In addition, the study on purinergic P2 receptor (induces intracellular Ca2+ increases) in pancreatic ductal adenocarcinoma confirmed that the combination of AR-C118925XX, a selective antagonist of P2RY2 receptor, and gemcitabine had a synergistic effect, prolonging the survival time of xenotransplantation PDAC mice (38). Here, AR is linked to pancreatic ductal adenocarcinoma.